Charles Schwab Investment Management Inc. Sells 15,524 Shares of Hologic, Inc. (NASDAQ:HOLX)

Charles Schwab Investment Management Inc. cut its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 1.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,527,101 shares of the medical equipment provider's stock after selling 15,524 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.66% of Hologic worth $124,398,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BOKF NA boosted its position in shares of Hologic by 6.4% during the 1st quarter. BOKF NA now owns 10,508 shares of the medical equipment provider's stock worth $800,000 after purchasing an additional 631 shares in the last quarter. Janus Henderson Group PLC grew its stake in Hologic by 29.5% in the first quarter. Janus Henderson Group PLC now owns 99,707 shares of the medical equipment provider's stock valued at $7,773,000 after acquiring an additional 22,732 shares during the period. B. Riley Wealth Advisors Inc. grew its stake in Hologic by 13.0% in the first quarter. B. Riley Wealth Advisors Inc. now owns 3,198 shares of the medical equipment provider's stock valued at $249,000 after acquiring an additional 367 shares during the period. California State Teachers Retirement System increased its holdings in shares of Hologic by 0.5% during the first quarter. California State Teachers Retirement System now owns 411,051 shares of the medical equipment provider's stock valued at $32,046,000 after acquiring an additional 1,988 shares in the last quarter. Finally, Tidal Investments LLC raised its position in shares of Hologic by 10.8% during the first quarter. Tidal Investments LLC now owns 16,901 shares of the medical equipment provider's stock worth $1,317,000 after purchasing an additional 1,654 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 0.9 %

Shares of NASDAQ:HOLX traded down $0.73 on Tuesday, reaching $79.00. 1,922,089 shares of the company traded hands, compared to its average volume of 1,595,139. The stock has a market capitalization of $18.35 billion, a P/E ratio of 23.72, a price-to-earnings-growth ratio of 2.49 and a beta of 0.98. The business's 50-day simple moving average is $80.38 and its 200 day simple moving average is $78.38. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 52 week low of $67.59 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. During the same quarter in the previous year, the company earned $0.89 earnings per share. Hologic's quarterly revenue was up 4.5% on a year-over-year basis. As a group, equities analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analyst Ratings Changes

HOLX has been the subject of several recent research reports. Raymond James upped their price target on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. Stephens reiterated an "overweight" rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Citigroup lowered shares of Hologic from a "buy" rating to a "neutral" rating and dropped their price target for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Mizuho reduced their price objective on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a research report on Tuesday, November 5th. Finally, Leerink Partners decreased their price objective on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.